|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index.
|
30911344 |
2019 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, higher adiponectin levels are associated with a higher risk of ESRD independent of conventional risk factors, BMI, and metabolic syndrome components.
|
31323071 |
2019 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
BEFREE |
The associations between elevated adiponectin and end-stage renal disease are well recognized and thought to be at least partially explained by reduced renal clearance.
|
27368123 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In both type 1 and type 2 diabetes (T2D) patients with DKD, elevated adiponectin serum levels have been observed, and adiponectin serum level is a prognostic factor of end-stage renal disease.
|
28402446 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Pooled analysis of GENEDIAB and GENESIS studies showed that baseline plasma adiponectin levels were higher in subjects with established/advanced DN at inclusion (P < 0.0001) and in subjects who developed end-stage renal disease (ESRD) at follow-up (P < 0.0001).
|
28499019 |
2017 |
|
Chronic kidney disease stage 5
|
0.300 |
Biomarker
|
disease |
RGD |
Changes of adiponectin and its receptors in rats following chronic renal failure.
|
24028144 |
2014 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Compared with controls, phosphorylation of the adiponectin downstream effector adenosine monophosphate-activated protein kinase (AMPK) was higher in ESRD while acetyl-CoA carboxylase phosphorylation (ACC-P) and carnitine palmitoyl transferase-1 (CPT-1) levels were lower.
|
25049200 |
2014 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, our study suggests that adipose tissue production of adiponectin contributes to the high plasma levels seen in end-stage renal disease.
|
23283133 |
2013 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These studies show that high serum adiponectin levels predict mortality and progression to end stage renal disease in type I diabetic patients.
|
18496510 |
2008 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Adiponectin levels were also higher in patients with ESKD compared with controls (P < .0005), and although levels were lower in the transplant group, they remained higher than in controls (P < .0001).
|
17697862 |
2007 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Markedly (P < 0.0001) elevated median plasma adiponectin levels were observed in ESRD patients (22.2 microg/mL), especially type 1 diabetic patients (36.8 microg/mL), compared to control subjects (12.2 microg/mL).
|
14675060 |
2004 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Although plasma levels of adiponectin, a recently discovered anti-inflammatory and antiatherogenic adipocytokine, are markedly elevated in ESRD, gene expression of adiponectin (ApM1) has not been analyzed in ESRD patients.
|
15200411 |
2004 |
|
Chronic kidney disease stage 5
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Clinically, high plasma adiponectin level was associated with low cardiovascular event rate in patients with chronic renal failure.
|
15096450 |
2004 |